Table S1. Details on limit and dose-response test results.

| Limit test results |  |  |  |  |  |  |  |  | Dose-response test results |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Familie | Abr | Mortality ${ }^{\text {a }}$ | Adhesion ${ }^{\text {a }}$ | \%1B+ ${ }^{\text {b }}$ | \%3B+ ${ }^{\text {b }}$ | Avidity ${ }^{\text {b }}$ | nb.* | Scoring ${ }^{\text {c }}$ | Log(EC50) | IC95\% | EC50 (mM) | IC95\% | Hill Slope | IC95\% | $\mathbf{R}^{2}$ | Ranking ${ }^{\text {d }}$ |
| TBP | TBP S-Pro | ns | ns | ns | ns | * | 1 | 7\% | nd | nd | nd | nd | nd | nd | nd | \#10 |
| TBP | TBP D-Glu | ns | ns | ns | ns | ** | 2 | 13\% | nd | nd | nd | nd | nd | nd | nd | \#9 |
| TBP | TBP Suc | ns | *** | ns | * | ** | 6 | 40\% | nd | nd | nd | nd | nd | nd | nd | \#6 |
| TBP | TBP L-Lact | ns | ns | ns | ns | ns | 0 | 0\% | nd | nd | nd | nd | nd | nd | nd | \#11 |
| TBP | TBP Pyr | ns | * | ns | ns | ns | 1 | 7\% | nd | nd | nd | nd | nd | nd | nd | \#10 |
| TBP | TBP L-Tart | ns | ** | ns | ns | * | 3 | 20\% | nd | nd | nd | nd | nd | nd | nd | \#8 |
| TBP | TBP L-Mal | ns | * | ns | ns | * | 2 | 13\% | nd | nd | nd | nd | nd | nd | nd | \#9 |
| TBP | TBP Malo | ns | ns | ns | ns | * | 1 | 7\% | nd | nd | nd | nd | nd | nd | nd | \#10 |
| TBP | TBP Br | ns | ns | ns | ns | ** | 2 | 13\% | nd | nd | nd | nd | nd | nd | nd | \#9 |
| TBP | TBP Lev | ns | ns | *** | *** | *** | 9 | 60\% | nd | nd | nd | nd | nd | nd | nd | \#5 |
| TBA | TBA Lact | ns | ns | ns | * | *** | 4 | 27\% | nd | nd | nd | nd | nd | nd | nd | \#7 |
| Bet | Bet-C8-Lac | *** | *** | *** | *** | ** | 14 | 93\% | 0.637 | [0.583-0.691] | 4.336 | [3.832-4.906] | 8.275 | [0.096-16.45] | 0.986 | \#3 |
| Bet | Bet-AMC12-Lac | *** | *** | ** | *** | *** | 14 | 93\% | -0.926 | [-0.991--0.861] | 0.119 | [0.102-0.138] | 1.358 | [0.967-1.749] | 0.981 | \#1 |
| Bet | Bet | ns | ns | ns | *** | ns | 3 | 20\% | nd | nd | nd | nd | nd | nd | nd | \#8 |
| Bet | BetO-C12-Lac | n/a | n/a | n/a | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | n/a | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | n/a | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | n/a |
| Bet | BetO-C8-Lac | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | n/a | n/a | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | $\mathrm{n} / \mathrm{a}$ | n/a |
| Cho | Cho-C12-Lact | *** | *** | ** | *** | *** | 14 | 93\% | -0.584 | [-0.649--0.518] | 0.261 | [0.224-0.304] | 6.553 | [-5.321-18.43] | 0.969 | \#2 |
| Cho | Cho-Cl | ns | ns | ns | ns | ns | 0 | 0\% | nd | nd | nd | nd | nd | nd | nd | \#11 |
| Cho | Cho-C8-Lact | *** | *** | ns | *** | *** | 12 | 80\% | nd | nd | nd | nd | nd | nd | nd | \#4 |
| Cho | Cho-C6-Lact | ns | ns | ns | * | ns | 1 | 7\% | nd | nd | nd | nd | nd | nd | nd | \#10 |
| Cho | Cho-C6-Lev | ns | ns | ns | ns | * | 1 | 7\% | nd | nd | nd | nd | nd | nd | nd | \#10 |

*, $\mathrm{p}<0.05 ; * *, \mathrm{p}<0.01 ;{ }^{* * *}, \mathrm{p}<0.001$ in comparison to the corresponding control; ns, not significant; $\mathrm{n} / \mathrm{a}$, not available; nd, not determined.
${ }^{\text {a }}$, for cell mortality and adhesion, only inductions in comparison to the control are considered.
${ }^{\mathrm{b}}$, for phagocytosis endpoints, only inhibitions in comparison to the control are considered.
${ }^{\text {c }}$, for each IL, the score represents the total number of asterisks expressed as a percentage of the maximal possible number of asterisks (ie. 5 endpoints x 3 asterisks $=15$ )


